Zimmer Biomet Holdings, Inc. reported $2.08 billion in sales and $300,000 million in operating margin for the quarter ending June 30, 2025. The second quarter beat expectations for revenue but not EPS.
Zimmer Biomet Delivers Solid Q2 – All Eyes on Robotics and Monogram
3 min read Premium comments
Zimmer Biometsecond quarter 2025 earningsIvan Tornos
| Zimmer Biomet Holdings, Inc. 2025 Report ($000s): 3 Months Ended 06/30/25 | ||||||
| 3 Month Sales | 6 Month Sales | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $1,942,000 | $2,070,300 | 6.61% | $3,832,200 | $3,986,400 | 4.02% | |
| Op Profit | Op Profit | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $351,300 | $300,000 | -14.60% | $617,200 | $592,300 | -4.03% | |
| 18.09% | 14.49% | 16.11% | 14.86% | |||
| EPS | EPS | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $1.18 | $0.77 | -34.7% | $2.01 | $1.68 | -16.4% | |
| 2025 Sales Estimate | 2026 Sales Estimate | |||||
| Consensus | Change | Consensus | Change | |||
| $8,000,000 | 3.12% | $8,240,000 | 3.00% | |||
Source: RRY Publications LLC
Zimmer Biomet closed the books on the second quarter of 2025 with $2.08 billion in sales and an operating margin of nearly $300 million, outpacing revenue expectations even as earnings per share fell short. For executives watching the orthopedic landscape, the quarter was less about numbers on the balance sheet and more about where Zimmer Biomet is placing its bets for the future.
A Strong Quarter, Headwinds and All
Chairman, President and CEO Ivan Tornos opened the earnings call by underscoring the resilience of the business. Despite an “80-basis point, 7-day headwind” and delayed international orders now sliding into Q3, Zimmer Biomet still managed 2.8% organic growth.
The company’s U.S. hips and knees franchises were the standout performers, reinforcing Zimmer Biomet’s dominance in core reconstructive markets.
Tornos raised the full-year organic revenue growth outlook to 3.5%–4.5% (excluding Paragon 28), while projecting Paragon 28 alone will contribute 270 basis points of growth in 2025. He also nudged up EPS guidance to $8.10–$8.30, citing stronger operational efficiency and less tariff drag than expected.
Betting Big on Robotics – and Monogram
The headline-grabber wasn’t hips or knees, but Zimmer Biomet’s pending acquisition of Monogram Technologies, maker of the first robot to complete a fully autonomous surgery with Monogram implants.
Tornos called it “very exciting and disruptive technology,” noting that fully autonomous robotics could complement Zimmer Biomet’s ROSA platform by offering surgeons a spectrum — from robotic assistance to hands-off precision.
“Not every surgeon will want a fully autonomous robot,” Tornos acknowledged, “but flexibility is built into our ecosystem of solutions.”
For executives, this is a bold play; Zimmer Biomet is positioning itself not just as a hardware and implant company, but as the orchestrator of surgical ecosystems, spanning ASCs, robotics, and advanced digital tools.
CFO Perspective: Focus on High-Growth Segments
CFO Suketu Upadhyay emphasized continued investment in ASCs and robotics, noting that early adoption of recent launches, coupled with commercial expansion, sets the stage for “second half acceleration.”
While acknowledging “room for improvement,” Upadhyay’s message was clear: Zimmer Biomet is steering capital toward the areas where orthopedic procedure volumes and margins are expanding fastest.
Market Questions: Is the Tide Turning?
Analysts probed whether softer market signals in June hinted at broader demand weakness. Tornos pushed back, saying the overall market remains “healthy and certainly above pre-COVID levels.”
While June was somewhat soft, April, May, and July were “very strong,” bolstered by a steady flow of hospital case volume. Importantly, waiting lists remain long, suggesting sustained demand well into 2026.
What It Means for Big Blue
Zimmer Biomet is sending three clear signals to competitors and partners alike.
- Core recon still pays the bills. Hips and knees remain strong, providing stability.
- Growth is in robotics, ASCs, and adjacencies. The Monogram deal could redefine Zimmer Biomet’s robotics playbook.
- Resilience matters. Navigating international delays and uneven market trends without missing a beat underscores operational discipline.
For investors, the message is that Zimmer Biomet is not just defending its turf — it’s preparing to lead the next wave of orthopedic innovation. And with fully autonomous robotics now in the mix, the competitive chessboard just got a lot more interesting.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.